跳至主要内容
临床试验/2022-501514-56-00
2022-501514-56-00已完成4 期

Bioequivalence of Testosterone Transdermal Gel in Healthy Female Subjects

Laboratorios Leon Farma S.A.1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年1月30日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
48
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Jorge Avilés

Scientific

Laboratorios Leon Farma S.A.

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Role of testosterone supplementation in poor responders on IVF outcome
CTRI/2017/10/010113Besins Healthcare India Private Limited
招募中
不适用
se of transdermal Testosterone in women with decreased sexual desire and tendency for aggressiveness: a double blind randomized clinical trialack or loss of sexual desireF52.0
RBR-27cqn5niversidade Federal de São Paulo - UNIFESP
已完成
2 期
The effect of transdermal testosterone gel300mcg daily on cognitive performance in older postmenopausal women: a placebo controlled trial over 26 weekscognition in older postmenopausal womenMental Health - Studies of normal psychology, cognitive function and behaviour
ACTRN12609000981224Monash University120
已完成
不适用
Impact of topical testosterone on lipid profile in women with decreased sexual desire: A randomized controlled double-blind study.Absence or reduction of sexual desireF03.835Hypoactive Sexual Desire Disorder
RBR-8kmydzjuniversidade federal de sao paulo
进行中(未招募)
不适用
Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus - TIMES 2Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass and strength and sexual dysfunction. A number of conditions can also be associated with decreased testosterone production including metabolic syndrome, type II diabetes mellitus, atherosclerosis, myocardial infarction and chronic heart failure
EUCTR2005-002607-17-DEProstrakan Pharmaceuticals Ltd520